88 related articles for article (PubMed ID: 7374860)
1. Preliminary results with the new cytostatic Penberol in ovarian carcinoma.
Novotná J; Andrysek O
Neoplasma; 1980; 27(1):77-82. PubMed ID: 7374860
[TBL] [Abstract][Full Text] [Related]
2. Survival of patients with advanced ovarian carcinoma treated with Penberol.
Novotná J; Andrysek O; Kobilková J; Laurová L
Neoplasma; 1983; 30(2):245-50. PubMed ID: 6302531
[TBL] [Abstract][Full Text] [Related]
3. Status report of Mayo Clinic studies.
Edmonson JH
Natl Cancer Inst Monogr; 1975 Oct; 42():167-8. PubMed ID: 1243994
[TBL] [Abstract][Full Text] [Related]
4. [Registration of cytostatic effects on cultured cells in vitro and their current significance for individualized chemotherapy of tumors in advanced ovarian carcinoma].
Ebeling K; Spitzbart H
Zentralbl Gynakol; 1977; 99(17):1041-54. PubMed ID: 579017
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
8. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
9. Clinical experiences with Penberol (cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid) administered to patients with advanced neoplasias.
Matejková V; Mottl V; Topol O; Petriková J; Rezabek K; Zabojová E
Neoplasma; 1977; 24(3):333-9. PubMed ID: 331122
[No Abstract] [Full Text] [Related]
10. One year maintenance of carboplatin in patients with epithelial ovarian cancer--a phase II study.
Safra T; Kovner F; Barak N; Inbar MJ; Ron IG
Isr Med Assoc J; 2006 Jan; 8(1):27-9. PubMed ID: 16450747
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
13. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
14. Therapy of advanced ovarian juvenile granulosa cell tumors.
Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
[TBL] [Abstract][Full Text] [Related]
15. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
[TBL] [Abstract][Full Text] [Related]
16. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
17. Epithelial ovarian cancer in Greece: a retrospective study of 1,791 patients by the Hellenic Cooperative Oncology Group (HeCOG).
Pectasides D; Papaxoinis G; Fountzilas G; Aravantinos G; Bamias A; Pavlidis N; Kalofonos HP; Timotheadou E; Samantas E; Briasoulis E; Skarlos DV; Economopoulos T; Dimopoulos MA;
Anticancer Res; 2009 Feb; 29(2):745-51. PubMed ID: 19331231
[TBL] [Abstract][Full Text] [Related]
18. Phase III trial of high-dose sequential chemotherapy with peripheral blood stem cell support compared with standard dose chemotherapy for first-line treatment of advanced ovarian cancer: intergroup trial of the AGO-Ovar/AIO and EBMT.
Möbus V; Wandt H; Frickhofen N; Bengala C; Champion K; Kimmig R; Ostermann H; Hinke A; Ledermann JA; ;
J Clin Oncol; 2007 Sep; 25(27):4187-93. PubMed ID: 17698804
[TBL] [Abstract][Full Text] [Related]
19. Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO.
Sehouli J; Stengel D; Mustea A; Camara O; Keil E; Elling D; Ledwon P; Christiansen B; Klare P; Gebauer G; Schwarz M; Lichtenegger W;
Cancer Chemother Pharmacol; 2008 Feb; 61(2):243-50. PubMed ID: 17393164
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.
Hitt R; Hornedo J; Colomer R; Mendiola C; Brandariz A; Sevilla E; Alvarez-Vicent J; Cortés-Funes H
Semin Oncol; 1995 Dec; 22(6 Suppl 15):50-4. PubMed ID: 8643971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
